The antitumor efficacy of P-S was also established in a pancreatic cancer xenograft model which encompass Kras wild-type (BxPC-3) and mutant (Mia PaCa-2) human pancreatic cancer cell lines. Here, KRAS is linked to pancreatic neoplasm.